Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by Drug Type
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Research Activities
4.1.1.2. Growing Cancer Prevalence
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.3. Opportunity
4.1.4. Government Initiatives
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. PEST Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. By Disease Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.1.2. Market Attractiveness Index, By Disease Type
9.2. Mild Anemia
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Moderate Anemia
9.4. Severe Anemia
10. By Treatment Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.1.2. Market Attractiveness Index, By Treatment Type
10.2. RBC Transfusions
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Erythropoiesis-stimulating agents (ESAs)
10.4. Iron Supplementation
11. By Drug Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.1.2. Market Attractiveness Index, By Drug Type
11.2. Epogen Injection
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Procrit Injection
11.4. Androxy Oral
11.5. Aranesp injection
11.6. Epoetin Alfa Injection
11.7. Others
12. By End User
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.1.2. Market Attractiveness Index, By End User
12.2. Hospitals
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Specialty Clinics
12.4. Ambulatory Surgical Centers
12.5. Cancer Research Centers
12.6. Cancer Rehabilitation Centers
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. The U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. The U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Dr. Reddy’s Laboratories Ltd.
15.1.1. Company Overview
15.1.2. Disease Type Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Pfizer Inc
15.3. Panacea Biotec Limited
15.4. SBI PHARMACEUTICALS CO., LTD
15.5. Tolero Pharmaceuticals, Inc.
15.6. Vifor Pharma AG
15.7. Therapure Biopharma Inc.
15.8. PharmaEssentia Corp.
15.9. PhytoHealth Corp
15.10. UBI Pharma Inc
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us